Jaap Verweij is Emeritus Professor of Medical Oncology and Chair of the Department of Medical Oncology of the Erasmus University Medical Centre. [1] He is currently Managing Director of the Cancer Drug Development Forum (CDDF). [2]
Verweij graduated as a medical doctor from the Free University Hospital in Amsterdam in 1978. He obtained his PhD in 1986.
He is an ESMO Faculty Member for Principles of Clinical Trials and Systemic Therapy. He is a former editor of the European Journal of Cancer, was President of the Connective Tissue Oncology Society (CTOS) from 2001 to 2002, [3] and is a former Vice-President of the European Organisation for Research and Treatment of Cancer (EORTC).
Verweij was elected a member of the Royal Netherlands Academy of Arts and Sciences in 2011. [4]
He has an h-index of 101 according to Semantic Scholar. [5]
Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
Robert Anthony "Robin" Weiss is a British molecular biologist, Professor of Viral Oncology at University College London and a member of the Nuffield Council on Bioethics.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Brian J. Druker, M.D. is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the chief executive officer of OHSU's Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.
Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
Michael John Peckham was a British oncologist and artist. As a cancer physician he is best known for his contribution to the treatment of testicular cancer. His paintings were first exhibited in 1962 and he showed in numerous mixed and solo exhibitions.
Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.
Johannes (Hans) Carolus Clevers is a Dutch molecular geneticist, cell biologist and stem cell researcher. He became the Head of Pharma, Research and Early Development, and a member of the Corporate Executive Committee, of the Swiss healthcare company Roche in 2022. Previously, he headed a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research and at the Princess Máxima Center; he remained as an advisor and guest scientist or visiting researcher to both groups. He is also a Professor in Molecular Genetics at Utrecht University.
Patrick Schöffski is a German medical doctor specializing in internal medicine, hematology and medical oncology.
Paul Alan Marks was a medical doctor, researcher and administrator. He was a faculty member and president at Memorial Sloan Kettering Cancer Center.
Takashi Sugimura was a Japanese biochemist, famous for research on chemical carcinogens. He received the Japan Prize for the contribution to establishment of fundamental concept on causes of cancer. He was elected as President of the Japan Academy on October 15, 2013, serving till 2016 and was replaced with Hiroshi Shiono.
Sir Stephen Philip Jackson, FRS, FMedSci is the Frederick James Quick Professor of Biology. He is a senior group leader at the Cancer Research UK Cambridge Institute and associate group leader at the Gurdon Institute, University of Cambridge.
Professor Richard James Gilbertson is a Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Li Ka Shing Chair of Oncology, and Director of the CRUK Cambridge Major Centre and the Children's Brain Tumour Centre of Excellence.
Luis Marti-Bonmati is a Spanish professor and researcher. He is the director of the Clinical Area of Medical Imaging Department at La Fe Polytechnic and University Hospital, and Head of Radiology Department at QuironSalud Hospital, Valencia, Spain. Marti-Bonmati is the founder of QUIBIM S.L., and is the Director of its Scientific Advisory Board. He is a member of the Spanish National Royal Academy of Medicine. He is also the director of the Biomedical Imaging Research Group (GIBI230) at La Fe Health Research Institute. The group is now included in the Imaging La Fe node at Distributed Network for Biomedical Imaging (ReDIB) Unique Scientific and Technical Infrastructures (ICTS), Valencia, Spain.
Jacques (Sjaak) Neefjes is a Dutch scientist who made breakthroughs in several research disciplines such as immunology, cell biology, chemistry, cancer biology, microbiology, and epidemiology. He is a professor at the Leiden University Medical Center. In 2020 he was one of four winners of the Spinoza Prize.
Bob Löwenberg is a clinical hematologist/investigator. He is a professor of hematology at Erasmus University Rotterdam.
Cornelis Joseph Maria Melief is a Dutch immunologuist specialising in cancer immunology and immunotherapy, with a focus on therapeutic cancer vaccines. He is emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center, and Chief Scientific Officer at ISA Therapeutics in Netherlands. He is known for his work in the field of cancer immunology, devising new cancer therapies based on the activation of the patient's own immune system.
Rolf Issels is a medical oncologist and biochemist. He performed the first regional hyperthermia in combination with chemotherapy in 1986.
Professor Susana Banerjee is a Consultant Medical Oncologist and Research Lead within the Gynaecology Unit at London's, The Royal Marsden. She is Professor in Women's Cancers and Team Leader at the Institute of Cancer Research.